Daiichi Sankyo Company, Limited

Hisamitsu Pharmaceutical Company, Inc.

Kyoto Pharmaceutical Industries, Ltd.

Masaki Miyazaki

Shigeo Kusumi

Keisuke Yoshida

Yuuichi Sugimoto

Kouichi Uoto

Ken Ishii

Hiroyuki Naito

Toru Taniguchi

Shoko Yoshida

Masaharu Inui

Rieko Takano

Masaki Setoguchi

Yoshihiro Ogura

Junya Kawai

Akitake Yamaguchi

Masafumi Ofuku

Shunsuke Takashima

Wakana Yokozeki

Masaya Fujii

Masafumi Ando

Teppei Fujimoto

Kazuya Otake

Takanori Wakabayashi

Masashi Aonuma

The present invention aims to provide a medicament capable of treating and/or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keap1 and Nrf2 and activating Nrf2. The present invention relates to a compound represented by the following formula (1): wherein each symbol is as described in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. In addition, the present invention also relates to a medicament containing the aforementioned compound, for the prophylaxis and/or treatment of diseases involving oxidative stress selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, radiation skin disorder, radiation mucosal disorder, cardiac failure, pulmonary arterial hypertension, Parkinson's disease, Friedreich's ataxia, multiple sclerosis, age-related macular degeneration, retinitis pigmentosa and glaucoma.

Benzotriazole compound

Packing box

Package

A compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity is provided. The present invention provides a dispiropyrrolidine derivative represented by the following formula (1), which has various substituents, inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity, wherein R, R, R, ring A, and ring B in formula (1) respectively have the same meanings as defined in the specification. 

Dispiropyrrolidine derivatives

There is provided compounds that inhibit interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. Compounds include imidazothiazole derivatives that can inhibit interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity.

Imidazothiazole derivatives having proline ring structure

Growing community of inventors

Tokyo, Japan

Masaki Miyazaki